本次合作产品的获批，有利于丰富公司在儿童呼吸系统疾病治疗领域的产品布局，增强公司在医药市场的竞争力。公司将积极组织开展相关产品的市场推广、生产和销售工作，推动产品在市场上的广泛应用，为患者提供更多的治疗选择，同时为公司创造良好的经济效益。由于本次获批的产品尚未形成销售，不会对公司近期业绩产生重大影响。Changchun High-Tech Industries (000661.SZ) issued an announcement, recently, the company's controlling subsidiary Changchun Jinsai Pharmaceutical Co., Ltd...
According to the Zhitong Finance APP, Changchun High-Tech Industries (000661.SZ) announced that recently, its controlling subsidiary Changchun Jin Sai Pharmaceutical Co., Ltd. (referred to as 'Jin Sai Pharmaceutical') and its subsidiary Changchun Jin Yi An Pharmaceutical Co., Ltd. (referred to as 'Jin Yi An') along with its partner Beijing Dongfang Yunjia Pharmaceutical Co., Ltd. (referred to as 'Dongfang Yunjia') have received approval for the listing of the children's Gold cough granules through the priority review and approval process by the National Medical Products Administration.
Children's Gold cough granules are a Type 1 innovative drug of Traditional Chinese Medicine declared by Dongfang Yunjia. This drug has the effects of clearing the lungs and resolving phlegm, and stopping coughs, and is used for cough caused by mild acute bronchitis with phlegm-heat obstructing the lungs in children, with symptoms of red tongue and thin yellow or greasy coating. The listing of this drug provides new treatment options for children suffering from mild acute bronchitis.
The approval of this cooperative product is beneficial for enriching the company's product layout in the treatment of pediatric respiratory diseases, and enhancing the company's competitiveness in the pharmaceutical market. The company will actively organize the market promotion, production, and sales of related products, promoting widespread application of products in the market, providing patients with more treatment options, and creating good economic benefits for the company. Since the approved product has not yet generated sales, it will not have a significant impact on the company's recent performance.
